+

WO1994023067A1 - Antigenes associes a des tumeurs reconnus par les lymphocytes et utilisations de ces antigenes - Google Patents

Antigenes associes a des tumeurs reconnus par les lymphocytes et utilisations de ces antigenes Download PDF

Info

Publication number
WO1994023067A1
WO1994023067A1 PCT/US1994/003507 US9403507W WO9423067A1 WO 1994023067 A1 WO1994023067 A1 WO 1994023067A1 US 9403507 W US9403507 W US 9403507W WO 9423067 A1 WO9423067 A1 WO 9423067A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
cell
hla
polypeptide
associated antigen
Prior art date
Application number
PCT/US1994/003507
Other languages
English (en)
Inventor
Edward B. Reilly
Herman N. Eisen
Theodore Tsomides
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to AU64960/94A priority Critical patent/AU6496094A/en
Publication of WO1994023067A1 publication Critical patent/WO1994023067A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing

Definitions

  • This invention relates to the field of tumor immunology, and specifically to a novel family of melanoma-specific antigens recognized by T cells.
  • T cells Specific antigen recognition by T cells is based on the binding of the T cell receptor (TCR) to a complex composed of antigenic peptide and a major histocompatibility complex (MHC) molecule [Bjorkman, P. J., et al. (1987) Nature 329: 512].
  • CD8+ cytotoxic T lymphocytes (CTL) recognize cell surface components formed by class I MHC glycoproteins and antigenic peptides.
  • Antigenic peptides arise by cleavage of endogenously synthesized proteins that are bound by newly synthesized class I molecules in the endoplasmic reticulum and subsequently transported to the cell surface [Townsend, A. and Bodmer, H. (1989) Ann. Rev. Immunol. 7: 601 ].
  • TIL tumor infiltrating lymphocytes
  • the HLA-A2.1 class I molecule a product of the HLA-A2.1 gene, is an effective antigen-presenting molecule for presentation of melanoma antigens to T cells [Crowley, N.J., et al. (1 990) Cancer Res. 50: 492 and Kawakami, Y. (1992) J. Immunol. 148: 638].
  • 660 TIL a long-term melanoma-specific T cell line and its autologous tumor target cell line (660 mel) have been established from a human melanoma tumor sample [Reilly, E.B. and Antognetti, G. (1991 ) Cell. Immunol. 135: 526].
  • Tumor cell CTL activity of 660 TIL is inhibited by several monoclonal antibodies. (MAB) including those against CD3, CD8 and HLA-A2 molecules, indicating that the effector cells are class l-restricted CD3+, CD8+ CTL that recognize melanoma antigen(s) in association with HLA-A2 molecules.
  • One aspect of the invention presents substantially pure tumor-associated antigens which can bind to HLA molecules on tumor and non-tumor cells and cause those cells to be recognized by and destroyed by T cells.
  • These antigens can be obtained by the purification methods disclosed herein using different T cells and/or tumor cells.
  • the T cells are preferably CTL and more preferably TIL.
  • the destruction is preferably by lysis of the cells.
  • the invention presents a substantially pure family of HLA-A2-associated tumor antigens, an example of which is T cell- specific melanoma antigens which when bound to HLA-A2 on a cell will cause the cells to be recognized and lysed by TIL.
  • These antigens are generally between 5 to 20 amino acids in length, more preferably between 5-1 5, and most preferably between 7 to 12 amino acids in length.
  • T cell-specific melanoma antigens are peptides such as mel Ag 906 or mel Ag 1007.
  • the molecular weight of mel Ag 906 is about 906 Dalton (D) with a ⁇ 10% margin of error.
  • the molecular weight of mel Ag 1007 is about 1007 Dalton (D) with a ⁇ 10% margin of error.
  • Another aspect of the invention presents the polypeptide(s) from which the tumor-associated antigens are derived.
  • Another aspect of the invention presents methods for purifying the tumor-associated antigens, preferably from tumor cells and by means of cytotoxicity tests using T cells, in particular TIL.
  • Another aspect of the invention presents methods for diagnosing cancer using the above tumor-associated antigens, the polypeptide(s) from which the tumor-associated antigens are derived, or the derivatives of the above, such as their nudeotide sequences.
  • Another aspect of the invention presents methods for identifying cancer therapeutics using the above tumor-associated antigens, and the polype ⁇ tide(s) from which the tumor-associated antigens are derived.
  • the cancer therapeutics identified thereby are also presented.
  • Another aspect of the invention presents vaccines and methods for vaccination using the above tumor-associated antigens, and the polypeptide(s) from which the tumor-associated antigens are derived.
  • Figure 1 presents the CTL activity of 660 TIL against its autologous tumor cell target, 660 mel.
  • Figure 2 presents tumor cell cytotoxic activity of 660 TIL after stimulation with cultured 660 mel.
  • Figure 3 presents the HLA-A2 affinity purification from 660 mel cells.
  • Figure 4 presents the cytotoxic activity of peptides derived from 660 mel HLA-A2 molecules and fractionated by reverse phase chromatography on a CI 8 column.
  • Figure 5 presents the cytotoxic activity of pooled peptide fractions 42-46 from the C18 column (see Figure 4) fractionated by reverse phase chromatography on a phenyl column.
  • Figure 6 presents the cytotoxic activity of pooled peptide fractions 40-41 from the phenyl column (see Figure 5) fractionated by reverse phase chromatography on a C4 column.
  • Figure 7 presents the cytotoxic activity of pooled peptide fractions 49-50 from the C4 column (see Figure 6) fractionated by reverse phase chromatography on a minibore C8-polymer column.
  • the present invention presents substantially pure tumor- associated antigens which can bind to HLA molecules on tumor and non-tumor cells and cause those cells to be recognized by and destroyed by T cells. These antigens can be obtained by the purification methods disclosed herein using different T cells and/or tumor cells.
  • the T cells are preferably CTL and more preferably TIL.
  • the destruction is preferably by lysis of the cells.
  • the invention presents a substantially pure family of HLA-A2- associated tumor-associated antigens, an example of which is T cell-specific melanoma antigens which when bound to HLA-A2 on a cell will cause the cells to be recognized and lysed by TIL.
  • These antigens are generally between 5 to 20 amino acids in length, more preferably between 5-1 5, and most preferably between 7 to 12 amino acids in length.
  • Examples of the T cell-specific melanoma antigens are peptides such as mel Ag 906 or mel Ag 1007.
  • the molecular weight of mel Ag 906 is about 906 Dalton (D) with a ⁇ 10% margin of error.
  • the molecular weight of mel Ag 1007 is about 1007 Dalton (D) with a ⁇ 10% margin of error.
  • the present invention also provides a description of the isolation and characterization of such antigens.
  • the invention further presents the polypeptide(s) from which such peptides are derived. These tumor antigens, their polypeptide(s) from which they are derived, and their derivatives may prove particularly useful as cancer diagnostics and therapeutics, including vaccines.
  • Ag is herein defined as antigen, except in the context of Ag 906 and Ag 1007 which are the names of specific peptides.
  • MAB is herein defined as monoclonal antibody.
  • MHC is herein defined as major histocompatibility complex.
  • T cells is herein defined as lymphocytes derived from the thymus.
  • Tuor-specific T cell is a T cell that recognizes a specific tumor.
  • Sources of tumor-specific T cells include but are not limited to: a tumor or tumor specimen and as such are designated TIL; primary lymph organs such as lymph nodes or spleen; and peripheral blood.
  • TIL may include both CTL and T helper cells, 660 TIL is a CTL.
  • TIL tumor infiltrating lymphocytes
  • CTL cytotoxic T lymphocytes.
  • Tumor-associated antigen is hereby defined as an antigen expressed by tumor.
  • T cell-specific tumor antigen is hereby defined as a tumor- associated antigen that is recognized by a T cell.
  • T cell-specific melanoma antigen denotes an antigen which is specific to melanoma and which is recognizable by a T cell.
  • HLA-associated tumor antigen is hereby defined as a tumor- associated antigen which can associate with HLA to form a complex.
  • this complex is recognizable by T cells with the same HLA phenotype as the tumor target cell expressing the tumor-associated antigen i.e., both cells are HLA-compatible.
  • HLA-A2-associated tumor antigen is hereby defined as a tumor- associated antigen which can associate with HLA-A2 to form a complex.
  • this complex is recognizable by HLA-A2+ T cells.
  • T cells may include CTL and are preferably derived from tumors, peripheral blood, spleens or primary lymph organs.
  • the most preferred T cell is TIL.
  • the most preferred TIL is 660 TIL.
  • Specific Ag recognition by T cells is based on binding of the T cell receptor to a complex composed of an antigenic peptide and an MHC molecule.
  • MHC antigens There are two main varieties of MHC antigens, namely class I and class II. There are dozens of distinct class I and class II antigens. Class I antigens (of which the HLA-A2 molecule is one) are present on almost all cells and it is the unique combination of class I MHC antigens that mark those cells of each individual as unique. Most cells express between two to four distinct class I antigens. Although there are dozens of class I MHC antigens, HLA-A2 is probably the most prevalent, present in about 50% of the Caucasian population. This means that, although these individuals still have distinct haplotypes (i.e.
  • HLA-A2-restricted melanoma-specific CTL also referred to as A2-restricted melanoma-specific CTL
  • A2-restricted melanoma-specific CTL are, therefore, T cells that recognize the combination of the HLA-A2 antigen associated with a small peptide.
  • the HLA-A2 molecule is a product of the HLA-A2 gene. Humans who express the A2 protein are classified as HLA-A2+. HLA-A2 class I molecule is also referred to as the A-2 protein. There are many subtypes of HLA-A2 molecules (e.g. A-2.1 , A-2.2, A-2.3, etc.) [Parnham, P., et al. (1991 ) Immuno ⁇ en. 33: 310], each of which is coded for by a different gene, although the HLA 2.1 subtype is the most prevalent. Mature peripheral T cells with an ⁇ (the most common) T cell receptor can be categorized into two major classes expressing either the CD4 or CD8 transmembrane glycoprotein. CD4+ T cells (which generally include T helper cells) recognize peptide fragments bound to MHC class II molecules, while CD8+ T cells (which generally include CTL) recognize peptide fragments bound to MHC class I molecules.
  • CD4+ T cells which generally include T
  • CTL epitopes are complexes composed of antigenic peptides and class I MHC molecules.
  • Antigenic peptides arise by cleavage of endogenously synthesized proteins that are bound by newly synthesized class I molecules in the endoplasmic reticulum and subsequently transported to the cell surface [Tsomides, TJ. and Eisen, H.N. (1991 ) J. Biol. Chem. 266: 3557].
  • a general scheme for isolation of such peptides consists of expansion of cultures of a melanoma cell line known to express the proper epitopes.
  • the use of this approach to identify medically relevant melanoma antigens could lead to determination of the amino acid sequences of these peptides and identification of the proteins from which they are derived. This information could provide a basis for diagnostic and therapeutic intervention.
  • Methods 1 and 2 There are several methods for obtaining the T cell-specific tumor antigens; disclosed herein are Methods 1 and 2.
  • Method 1 involves purifying antigens from the membrane of tumor cells.
  • the antigens are selected for their binding to HLA.
  • Such selection can be achieved using HLA affinity chromatography.
  • the resulting peptides are then purified by HPLC fractionation. Peptides from each HPLC fraction are then mixed with an HLA- compatible non-tumor target cell and selected for their ability to induce lysis of those target cells by T cells. That is, the T cell recognizes the complex of HLA and the tumor-associated antigen, and thereby bind to the non-tumor cell and causes its lysis.
  • the tumor cell, non-tumor cell and T cell have to be HLA-compatible.
  • the tumor cell and T cell can be autologous.
  • the non-tumor cell can be non-autologous.
  • Method 2 does not rely on HLA affinity columns, therefore, the non-tumor cell (target cell) need not be HLA-compatible with the tumor cell; it needs only be HLA-compatible with the T cell (effector cell) in the test for cytotoxicity.
  • the tumor, non-tumor, and T cells need not be autologous.
  • the T cell is preferably derived from tumor, lymph, spleen, or peripheral blood. More preferably, the T cell is a CTL.
  • a T cell which is specific to a particular tumor i.e. a tumor-specific T cell
  • a tumor-specific T cell is used to detect the tumor-associated antigen derived from the specific tumor.
  • the tumor is melanoma and the tumor-specific T cell is a melanoma- specific T cell, i.e. a T cell which recognizes a melanoma tumor cell.
  • the tumor-specific T cell Upon recognition of its target tumor cell, the tumor-specific T cell is capable of lysing that target cell or releasing lymphokines or cytokines.
  • Tumor cell lines and T cells which are specific to them are known in the art and can be obtained by methods known in the art (see e.g. Reilly, E.B. and Antognetti, G. (1991 ) Cell. Immunol. 135: 526 and Topalian, S.L., et al. (1987) J. Immunol. Methods 102: 127).
  • the T cell is a melanoma-specific T cell line 660 TIL; and the tumor cell is a melanoma cell line 660 mel.
  • TIL melanoma-specific T cell line 660 TIL
  • tumor cell is a melanoma cell line 660 mel.
  • other tumor cells include those from colon, ovarian, cervical, lung, breast, prostate, and renal tumors.
  • T cells may preferentially recognize different tumor-associated antigens in the pool of HPLC fractions from the same tumor cell.
  • different tumor cells may express different tumor-associated antigens that are recognized by same or different T cells.
  • the tumor-associated antigen which would be of wide use would be the antigen which is widely expressed on the tumor cells of different individuals.
  • This tumor-associated antigen can be either recognized by a specific T cell of an individual or T cells of different individuals. The following describes Method 1.
  • T cell epitopes may be expressed at levels as low as
  • MHC-tumor-associated antigen complexes 100 molecules per cell, the cell expansion required may be substantial, leading to the generation of more than 10 1 • cells.
  • Detergent solubilized membranes prepared from these cells may then be passed over antibody affinity columns to isolate class I MHC molecules to which the tumor-associated antigens are complexed (herein called the "MHC-tumor-associated antigen complexes"). This can be achieved using methods known in the art.
  • the MHC-tumor-associated antigen complexes are then denatured to release the tumor-associated antigens. This can be achieved using acidic treatment with methods known in the art, such as incubation with trifluoroacetic acid.
  • the released tumor- associated antigens are then collected by ultrafiltration [as described in Udaka, K., et al. (1992) Cell 69: 989] and subjected to HPLC fractionation. This is required since the mixture of tumor- associated antigen released from MHC molecules is very complex.
  • Tumor-associated antigen fractions are tested for biological activity on the basis of ability to sensitize MHC-compatible non- tumor target cells for susceptibility to lysis by T cells.
  • the fractions can be tested for biological activity on the basis of ability to sensitize MHC- compatible non-tumor target cells for susceptibility to lysis by melanoma-specific CTL, preferably by TIL, and more preferably by 660 TIL.
  • active fractions can be pooled and re- fractionated on HPLC under different sets of conditions for additional purification.
  • Successive reverse phase columns such as HPLC are the preferred purification methods because, unlike ion exchange columns and gel filtrations, the antigens are not in salt or non-volatile buffers.
  • reverse phase columns no desalting step is required and the fractions can be directly tested for cytotoxic activity, thus avoiding further loss of antigens, which is crucial in view of the potentially miniscule amounts of these antigens expressed by the cells.
  • Examples of reverse phase columns are those using alkyl sidechains (e.g. CI , C2, C4, and CI 8), and cyano sidechains.
  • the CI 8, phenyl, C4, C8-polymeric fractionations can be employed in any order.
  • the quantity, purity and molecular weight of the tumor-associated antigens in the active HPLC fractions can be assessed by physical means such as mass spectroscopy.
  • the quantity of material present will determine the approach to be used for amino acid sequence analysis. Sequencing by Edman degradation generally requires >10 pmol of material. Therefore, the isolation of less material will necessitate the use of tandem mass spectrometry to generate sequence information.
  • Method 2 involves an acid extraction of low molecular weight materials from cells.
  • the tumor cells are acid extracted, and peptides of less than 10,000 daltons are recovered by ultrafiltration methods known in the art.
  • the tumor cells can be extracted in TFA, centrifuged at 31 ,000 x g for 30 min and the supernatant subjected to ultrafiltration through a
  • the purified tumor-associated antigen can be determined to be T cell-specific tumor antigen by several means.
  • the first means is disclosed under Method 1 , wherein the determinant is the ability of the tumor-associated antigen to render non-tumor cell susceptible to lysis by T cells.
  • T cells are preferably CTL and TIL.
  • the determinant can be the ability of the tumor-associated antigen to cause non-tumor cell to trigger the release of cytokines or lymphokines by T cells.
  • T cells are preferably CTL and helper T cells.
  • the cytokines or lymphokines that can be tested include: interferons, interleukins, and granulocyte macrophage colony stimulating factors.
  • the methods for determining the release of cytokines are known in the art, such as enzyme-linked immunoabsorbent assay (ELISA) [Schwartzentruber, D.J., et al. (1991 ) J. Immunol. 146: 3674] and polymerase chain reaction (PCR) [Carding, S.R., et al. (1992) i Immunol. Methods 15: 277].
  • ELISA enzyme-linked immunoabsorbent assay
  • PCR polymerase chain reaction
  • the tumor-associated antigens such as (an) active peptide(s)
  • the peptide(s) will be purified using methods known in the art, for example, by CI 8 reverse phase HPLC (Vydac, Hesperia, CA) and biological activity will be confirmed by the ability to reconstitute epitopes for the T cell used as effector cells, e.g. in the Example below, the effector cell is HLA-A2-restricted 660 TIL.
  • Class I HLA-associated tumor Ags purified by the method disclosed herein are preferably recognized by class-l HLA- restricted T cells.
  • the Ags are expressed in HLA-A2+ tumor cells or are associated with HLA-A2+ molecules on the surface of tumor cells.
  • These Ags may be recognized by T cells derived from tumors (TIL), peripheral blood or primary lymph organs such as lymph nodes and spleen.
  • TIL tumors
  • peripheral blood or primary lymph organs such as lymph nodes and spleen.
  • T cells Methods for growing, harvesting and maintaining T cells in general, and HLA-A2+ T cells in particular, are known in the art and are described [e.g., Topalian, S.L, et al. (1987) J. Immunol. Methods 102: 127 and Reilly, E.B., et. al. (1990) J. Immunol. Methods 126: 273].
  • the tumor-associated antigen Once the tumor-associated antigen has been sequenced, it can also be cloned into a host cell and produced recombinantly.
  • the tumor-associated antigen isolated and purified as disclosed in this patent application may have been derived by any of the following means:
  • starting polypeptide could be overexpressed in the tumor cell compared to lower levels or absence of expression in normal cells; (2) the gene for a full length protein (another example of “starting polypeptide") expressed in an altered form may result in expression in the tumor cell of an altered form of a full length protein compared to a normal cell;
  • a full length protein (as described in (1 ) and (2) above) could be expressed in the tumor cell and processed to generate a polypeptide of a different length expressed either intracellularly or on the cell surface in association with HLA molecules (the polypeptide is herein termed "end-product polypeptide");
  • a full length protein (as described in (1 ) and (2) above) could be expressed in the tumor cell and processed to produce various peptides which are present in the cell or expressed on the cell surface in association with HLA molecules (these polypeptide(s) are also termed "end-product polypeptide(s)").
  • Different polypeptides can be expressed with different HLA molecules. These polypeptides may arise by differential processing of the same full length protein or, in fact, processing of different full length proteins. That is, a specific polypeptide may be expressed by a HLA-A2+ individual which would complex with the HLA-A2 protein and be recognized by a T cell, whereas another polypeptide may be expressed by the same or a different gene in an individual expressing another HLA protein (such as HLA-B7) which would complex with that HLA protein and be recognized by a T cell.
  • the T cells in both cases may not be the same; nor the tumor cells from which the polypeptides are derived.
  • another aspect of this invention presents other T cell-specific tumor antigens which can associate with HLA molecules, and which can be obtained by the purification methods disclosed herein using different T cells and/or tumor cells.
  • polypeptide encompassed within this invention and the term "polypeptide”, would be the tumor-associated antigen, the differently processed or expressed polypeptides, and the full length polypeptides (whether starting or end-product polypeptides) which may be the origins of the tumor-associated antigen purified by the method disclosed herein and which may be found in the pool of polypeptides purified by this means. That is, within the pool of the purified polypeptides, there may be polypeptides that are at different stages of the processing or modification phases.
  • the T cell-specific melanoma antigens such as mel Ag 906 and mel Ag 1007, can be fragments of larger polypeptides or the processed products of starting polypeptides or groups of polypeptides, or fragments of end-product polypeptides.
  • the starting polypeptides would also be included within this invention.
  • the starting and end-product polypeptides share at least 78-100%, and more preferably at least 87-100%, and most preferably, 100% homology in amino acid residues with the tumor- associated antigen purified by the method disclosed herein for the segment in which the starting (or end-product) polypeptide and the tumor-associated antigen are most closely aligned.
  • the preferred example of this polypeptide is Class 1 HLA- associated tumor antigen, and more preferably an HLA-A2- associated tumor antigen and its starting and end-product polypeptides.
  • Characterization of a tumor-associated antigen should make it possible to determine the mature protein from which it is derived in one of two ways.
  • the identity of the parent protein may be deduced on the basis of sequence homology searches. If necessary, the gene for the protein of interest could be determined by screening DNA libraries, prepared from the tumor cells from which the tumor-associated antigen originated, with oligonucleotide probes corresponding to the peptide sequence.
  • the active peptide derived from 660 mel will be reconstituted with HLA-A2 to determine if this CTL epitope can be recognized by other A2-restricted melanoma- specific CTL. This will provide a better understanding for the existence of shared melanoma antigens.
  • polypeptides obtained by the methods disclosed in this patent application can be used to diagnose cancer, serve as cancer therapeutics or vaccines for the cancers from which the tumor cells are derived from.
  • These polypeptides may also be expressed by tumor cells besides those that they are derived from; thus, the cancers to be detected, treated, or vaccinated against can be those other than the original tumor cells.
  • HLA-A2 derived CTL epitopes are especially likely to have broad utility in the development of diagnostics or therapeutics for melanoma because of the frequency of HLA-A2 expression.
  • Several possible modes of action for diagnostic intervention are envisioned based on host reactivity to these antigens. For example, candidates at risk for melanoma could be screened for the presence of specific antigens by either immunoassays or DNA probes. PCR-based assays may be also prove useful for sensitive detection of antigens.
  • a skin test to asses melanoma-specific CTL activity may prove useful as a diagnostic tool. It is also possible that an in vitro correlation of the skin test, whereby the effector function of melanoma-specific CTL may be determined from a source such as peripheral blood, could prove valuable as well as non-invasive.
  • T cell-specific antigen recognized by melanoma-specific T cells upon identification of a T cell-specific antigen recognized by melanoma-specific T cells and the full length protein from which it is derived, it may be possible to develop diagnostic tests for their presence which may be useful in cancer detection in individuals at risk for melanoma.
  • T cell-specific tumor antigen such as a peptide, or full length protein from which it is derived
  • skin specimens obtained upon biopsy, will be used as test substrates for antibody reactivity. Although it is unlikely that a peptide-specific MAB will be able to react with a T cell Ag buried within the cleft of the HLA molecule on the cell surface, other methods of antibody reactivity will also be analyzed to detect intracellular antigens.
  • immunofluorescence and ELISA on cell extracts, histological samples, lysed cells, biological fluid such as blood, serum, urine, breast secretion, mucous of lungs, cervical swab, cerebral fluid, and synovial fluid. These samples can be taken, for example, for detecting colon, ovarian, lung, breast, cervical, prostate and renal tumors. Both immunofluorescence and ELISA on cell extracts, histological samples, lysed cells, biological fluid such as blood, serum, urine, breast secretion, mucous of lungs, cervical swab, cerebral fluid, and synovial fluid. These samples can be taken, for example, for detecting colon, ovarian, lung, breast, cervical, prostate and renal tumors. Both immunofluorescence and ELISA on cell extracts, histological samples, lysed cells, biological fluid such as blood, serum, urine, breast secretion, mucous of lungs, cervical swab, cerebral fluid, and synovial fluid. These samples can be taken, for example,
  • ELISA procedures are well known to those who are skilled in the art.
  • Polyclonal and monoclonal antibodies directed against these T cell-specific tumor antigens can be made using methods known in the art. For example, antibodies can be produced by injecting a host animal such as rabbit, rat, goat, mouse etc. with the tumor- associated antigen and fragments thereof, alone or conjugated to an appropriate carrier if required to elicit an antibody response. It will be appreciated by those skilled in the art that the MAB can be produced, for example, by means of the hybridoma techniques.
  • Skin specimens obtained by biopsy may be used as source of RNA prepared by conventional methods.
  • a chemically tagged or radiolabeled oligonucleotide encoding the T cell-specific tumor antigen can be used as a hybridization probe to detect the presence or prevalence of the messenger RNA (mRNA) of the T cell-specific tumor antigen.
  • mRNA messenger RNA
  • hybridization, PCR or ligase chain reaction (LCR) can be used to detect the altered gene or its mRNA from its wild type counterparts.
  • LCR ligase chain reaction
  • the samples that can be tested include biological fluid, tissue or cells.
  • oligonucleotides specific for the T cell-specific tumor antigen can be used to prime the PCR from template RNA isolated from biopsied samples by standard methods known in the art.
  • An in vivo skin test may provide a quick and easy diagnostic test for detection of melanoma- specific T cells and thereby serve as a useful prognosticator of melanoma in patients.
  • Synthetic peptide(s) corresponding to the T cell- specific tumor antigen will be solubilized in balanced salts and injected intradermally. The site of the injection will be monitored for several days for evidence of a delayed type hypersensitivity (DTH) reaction which would be indicative of specific T cell immunoreactivity.
  • DTH delayed type hypersensitivity
  • the ability to use skin tests to monitor specific cytotoxic T cell activity has been demonstrated in animal models [Kundig, T.M., et al. (1992) Proc. Natl. Acad. Sci. USA. 89: 775].
  • T cells enriched from peripheral blood samples of patients to be screened will be placed in short term culture with a HLA-A2 melanoma cell line expressing the T cell-specific tumor antigen. Increases in specific cytokine production, as measured by either ELISA or PCR, will be used to indicate specific T cell immunoreactivity. Alternatively, specific T cell immunoreactivity may be measured against HLA-A2 target cells sensitized in culture with the T cell-specific melanoma antigen. Procedures for setting up short-term cultures and using ELISA or PCR-based methods to screen for immunoreactivity are known to those skilled in the art.
  • identification of melanoma-specific antigens may provide the basis for targeted anticancer therapy.
  • Immunization of HLA-A2+ melanoma patients with melanoma antigens may be an effective scheme for stimulating melanoma-specific CTL and reducing or eradicating tumor cells.
  • T cell-specific melanoma antigen identified by the methods outlined herein may be the basis of useful immunotherapeutic strategies such as the following.
  • T cell-specific melanoma antigens may be used as vaccines to protect individuals at risk for melanoma.
  • T cell-specific tumor antigens would be administered to induce the expansion of protective T cells.
  • Optimal routes of administration, dose and formulation to effect specific CTL function would be explored.
  • the above therapeutics can be similarly applied to other tumor-associated antigens obtained by the methods disclosed herein for treatments of the same or different tumors.
  • the invention also covers such pharmacological compositions such as the vaccines and therapeutic compositions disclosed herein.
  • 660 mel and 660 TIL which are autologous (derived from the same individual), 663 mel [Reilly, E.B. and Antognetti, G. (1991 ) Cell. Immunol. 135: 526], and M21 [Gillies, S.D. and Wesolowski, J.S. (1990) Hum. Antibod. Hvb domas 1 : 47] were used.
  • 660 TIL are TIL that recognize 660 mel, but more specifically they recognize the combination of a peptide associated with HLA-A2 antigens on the surface of the 660 mel. Expansion of 660 mel. 660 mel were grown in 850 cm 2 roller bottles until confluent. Cells were recovered by treatment with 5 mM EDTA (pH 8.0), washed once with phosphate-buffered saline (PBS) and stored frozen at
  • Membranes were passed over four affinity columns arranged in series as follows: Sepharose only, mouse pooled immunoglobulin-Sepharose (to bind Fc receptors and other membrane proteins) and two successive PA2.1 -Sepharose (anti-HLA-A2) (Monoclonal antibody
  • Purified HLA-A2 was concentrated to remove unbound peptides by ultrafiltration at 5000 x g (Centricon C10) and was then denatured with 1.0% trifluoroacetic acid [Rotzschke, O., et al. (1990) Science 249: 283] for 60 min at 37°C. The released peptides were collected by ultrafiltration at 5000 x g and subjected to HPLC fractionation.
  • HPLC fractionations were performed on reverse phase columns (CI 8, phenyl, C4, C8-polymeric; commercially available from Vydac, Hesperia, CA) using a binary gradient system and detection by ultraviolet absorbance at 220 nm.
  • solvent A 0.1 % trifluoroacetic acid (TFA) in H2 ⁇
  • solvent B 0.085% TFA in acetonitrile
  • a gradient of between 0.25 and 1 % B per minute and a flow rate of 1 ml/min.
  • RPMI with 10% heat-inactivated fetal bovine serum were then added at a E:T ratio of 50:1 in a final volume of 200 ⁇ l.
  • the cells were incubated at 37 C for 4 h and the amount of 51 Cr released into the extracellular medium was determined. The percent specific lysis was calculated as 100 x ( 51 Cr released - spontaneous release)/(total release in HCI - spontaneous release).
  • Toxicity controls consisted of peptide plus 51 Cr- labeled target cells without addition of 660 TIL.
  • the active fractions from the final chromatography were analyzed by mass spectrometry to determine the molecular weight.
  • 660 TIL were tested for lytic activity against both autologous and non-autologous melanoma tumor cell lines.
  • Figure 1 presents the CTL activity of 660 TIL against its autologous tumor cell target, 660 mel.
  • 660 TIL were maintained in culture for several months and then stimulated repeatedly over the course of several weeks with the addition of 660 mel cells to the culture at a T cell/target cell ratio of 10:1.
  • Figure 2 presents tumor cell cytotoxic activity of 660 TIL after stimulation with cultured 660 mel. Lytic activity of TIL stimulated once (open bars) or three times (hatched bars) was determined in 4 h 51 Cr release assays at E:T ratios shown. Error bars represent standard deviation.
  • Figure 2 shows that multiple rounds of tumor cell stimulation over the course of several weeks increased the specific 660 TIL cytotoxic activity to greater than 70% lysis at an E:T ratio of 50:1.
  • 660 TIL are CD3+.
  • CD8+ CTL that Recognize A ⁇ Associated with Class I MHC Molecules The effect of several MAB on the lysis of autologous melanoma target cells by 660 TIL was determined as shown in Table I.
  • Table I presents the effect of MAB on the lysis of 660 mel cells by 660 TIL at different E:T ratios.
  • MAB specific for CD3 (OKT3 is available from the American Type Culture Collection, Rockville, MD , herein referred to as ATCC.
  • OKT3's ATCC Accession No. is CRL 8001 ), CD4 (OKT4, ATCC Accession No. CRL
  • d Inhibition by OKT8 is enhanced in the presence of higher concentrations of the MAB. ln agreement with classical CTL function, 660 mel lysis by 660 TIL was inhibited by MAB to CD3, CD8 and class I MHC molecules. MAB against the intercellular adhesion molecules ICAM and LFA-1 also inhibited lysis of tumor cells.
  • Table 2 presents the effect of anti-HLA-A2 MAB on the lysis of 660 mel cells by 660 TIL at different E:T ratios.
  • MAB specific for HLA-A2 (BB7.2, ATCC Accession No. HB82) as well a control MAB specific for another HLA molecule, HLA-B7 (BB7.1 , ATCC Accession No. HB56) were added to radiolabeled 660 mel cells at a final concentration of 50 ⁇ g/ml and incubated for 30 min at room temperature. 660 TIL were then added, incubation was continued for 4 h at 370C and the assay was harvested.
  • Table 2 shows that the recognition of 660 mel by 660 TIL was inhibited by MAB against HLA-A2 (BB7.2), but not by MAB against directed another MHC molecule, HLA-B7 (BB7.1 ). The recognition of Ag on the established melanoma cell line is, therefore, restricted by HLA-A2.
  • 660 Mel Cells Can Be Expanded to Lar ⁇ e Numbers for Extraction of Cell Membranes: 5 x 10 1 1 660 mel cells were grown as monolayers in more than 4000 850 cm 2 roller bottles and recovered by treatment with 5 mM EDTA (pH 8.0).
  • membranes were extracted from batches of 5 x 10 ⁇ 0 cells by lysis in hypotonic medium [10 mM Tris-HCl (pH 8.1 ), 1 mM MgCl2, 1 mM KCI] in the presence of 100 ⁇ M phenylmethanesulfonyl fluoride, 200 ⁇ M dithiothreitol and 0.02% NaN3 at about 2.5 x 10 8 cells/ml hypotonic media. Extracted cells were centrifuged at 1000 x g for 10 min at 4°C . The supernatants were collected and the cell pellet was re-extracted.
  • hypotonic medium 10 mM Tris-HCl (pH 8.1 ), 1 mM MgCl2, 1 mM KCI
  • the affinity columns were prepared by Staphylococcal protein A purification of the MAB, periodate oxidation of the carbohydrate moiety in the Fc domains and covalent coupling of about 3-4 mg of the MAB per ml of hydrazide-modified Sepharose. Final coupling yields were generally in the range of 1.5-2.5 mg MAB/ml Sepharose. Columns were first washed extensively with ten column volumes of 0.1 M Tris-HCl (pH 8.0),
  • wash buffer 10 ⁇ M phenylmethanesulfonyl fluoride
  • wash buffer 10 ⁇ M phenylmethanesulfonyl fluoride
  • the columns were separated and washed with -ten column volumes of each of the following: 1 ) wash buffer; 2) 1 M Tris-HCl (pH 8.0), 0.2% Brij 58; and 3) 0.02 M Tris-HCl (pH 8.0). Bound material was eluted from the columns with 50 mM diethylamine-HCI (pH 1 1 ) and 2 ml fractions were collected into tubes containing 0.2 ml
  • FIG. 3 presents the HLA-A2 affinity purification from 660 mel cells. Membranes extracted from 660 mel cells were passed through affinity columns prepared with MAB PA2.1 , ATCC HB1 17 (anti-HLA-A2) and after extensive washing of the column specifically bound HLA-A2 molecules were eluted in the presence of 50 mM diethylamine-HCI (pH 8.0).
  • Figure 3 shows the results of a typical elution profile from the mouse immunoglobulin and the two successive PA2.1 columns.
  • Figure 3 presents the HLA-A2 affinity purification from 660 mel cells. HLA purity was assessed by SDS/PAGE. Yields and purity were further determined by quantitative amino acid analysis.
  • HLA-A2- ⁇ o»nd Peptide Elu ion Purified HLA-A2 was purified and concentrated to remove unbound peptides by ultrafiltration at 5000 x g (Centricon CI 0) and then denatured with 1.0% trifluoroacetic acid for 60 min at 370C. The released peptides were collected by ultrafiltration at 5000 x g and subjected to HPLC fractionation.
  • HPLC fractionations were performed on reverse phase columns CI 8, phenyl, C4, C8-polymeric using a binary gradient system and detection by ultraviolet absorbance at 220 nm.
  • solvent A 0.1 % trifluoracetic acid (TFA) in H2O
  • -solvent B 0.085% TFA in acetonitrile
  • a gradient of between 0.25 and 1 % B per min and a flow rate of 1 ml/min.
  • solvent A was 125 mM triethylamine acetate (TEAAc) in H2O (pH
  • Figure 4 presents the cytotoxic activity of peptides derived from 660 mel HLA-A2 molecules.
  • Peptides released from HLA-A2 molecules by treatment with trifluoroacetic acid were fractionated by reverse phase chromatography on a CI 8 column. Fractions were collected at 1 min intervals at a flow rate of 1 ml/min and subjected to standard cytotoxicity assays using 51 Cr- labeled JY cells (an HLA-A2+ non-tumor EBV-transformed human B cell line). The two major peaks of cytotoxic activity corresponded to fractions 42-46.
  • Figure 5 presents the cytotoxic activity of pooled peptide fractions 42-46 from the CI 8 column (see Figure 4) fractionated by reverse phase chromatography on a phenyl column. Fractions were collected at 1 min intervals at a flow rate of 1 ml/min and subjected to standard cytotoxicity assays using 5 1 Cr-labeled JY cells. The major peak of cytotoxic activity corresponded to fractions 40-41.
  • Figure 6 presents the cytotoxic activity of pooled peptide fractions 40-41 from the phenyl column (see Figure 5) fractionated by reverse phase chromatography on a C4 column. Fractions were collected at 1 min intervals at a flow rate of 1 ml/min and subjected to standard cytotoxicity assays using 1 Cr-labeled JY cells. The major peak of cytotoxic activity corresponded to fractions 49-50.
  • Figure 7 presents the cytotoxic activity of pooled peptide fractions 49-50 from the C4 column (see Figure 6) fractionated by reverse phase chromatography on a minibore C8-polymer column. Fractions were collected at 0.5 min intervals at a flow rate of 0.25 ml/min and subjected to standard cytotoxicity assays using 51 Cr- labeled J-Y cells. Active fractions correspond to 83-85.
  • Mass Spectrometrv to Characterize Active Peptide The active fractions from the final chromatography (as represented by fractions 83-85 in Figure 7) were analyzed by mass spectrometry to determine purity and molecular weight similar to the method disclosed in
  • mel Ag 906 The molecular weight of mel Ag 906 is about 906 Dalton (D) with a ⁇ 10% margin of error.
  • mel Ag 1007 The molecular weight of mel Ag 1007 is about 1007 Dalton (D) with a ⁇ 10% margin of error.
  • the amino acid sequence can be determined by similar tandem mass spectrometry.
  • the partial DNA sequence of the polypeptide can be used as hybridization probes to identify the gene which encodes the polypeptide from a cDNA library prepared from the tumor cell line from which the polypeptide has been purified from or any tumor cell line.
  • the polypeptide can also be identified. This can be achieved using methods known in the art.
  • HLA-A2-Associated Epitopes are Shared bv Different Melanoma Lines:
  • the active peptide derived from 660 mel will be reconstituted with HLA-A2 to determine if this CTL epitope can be recognized by other A2-restricted melanoma-specific CTL. This will provide a better understanding for the existence of shared melanoma antigens.
  • 660 TIL derived from a solid tumor sample of a patient with malignant melanoma, is a CD3+, CD8+ CTL that has specific lytic activity directed towards its autologous tumor cell line, 660 mel.
  • the peptide recognized by 660 TIL is a short peptide of about 7-10 amino acids in length associated with HLA-A2 molecules expressed on the surface of 660 mel.
  • 660 mel cells are amenable to large scale expansion in tissue culture while still retaining their properties as antigen-specific-target cells. Cells prepared in this manner have been used as a source of membranes for the subsequent affinity purification of complexes of HLA-A2 molecules and their associated peptides.
  • HLA-A2- restricted epitopes may provide the basis for significant diagnostic or therapeutic intervention. For example diagnosis based on host reactivity to these antigens may involve either immuno- or DNA-based assays. Both in vivo and in vitro applications may be considered. Therapeutic intervention may involve immunization of cancer patients with melanoma antigens for the purpose of stimulating melanoma-specific CTL and eradicating tumor cells.
  • Deposit of Biological Materials The following cell line has been deposited with the American Type Culture Collection (ATCC), 12001 Parklawn Drive, Rockville, Maryland 20852 (USA) pursuant to the provisions of the Budapest Treaty.
  • the present invention is not to be considered limited in scope by the deposited cell line, since the deposited cell line is intended only to be illustrative of particular aspects of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne le domaine de l'immunologie des tumeurs et plus particulièrement une nouvelle famille d'antigènes spécifiques aux mélanomes, reconnus par les lymphocytes T. Ces antigènes, comme tous les épitopes des lymphocytes T se présentent sous la forme de petits peptides associés à des antigènes du complexe majeur d'histocompatibilité sur la surface des cellules. L'invention concerne également des procédés et des produits pour la purification et la détermination en séquences de ces peptides. Sont également présentées des applications dans le domaine du diagnostic et de la thérapie du cancer.
PCT/US1994/003507 1993-03-31 1994-03-31 Antigenes associes a des tumeurs reconnus par les lymphocytes et utilisations de ces antigenes WO1994023067A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64960/94A AU6496094A (en) 1993-03-31 1994-03-31 Tumor-associated antigens recognized by t cells and the uses of these antigens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4080093A 1993-03-31 1993-03-31
US040,800 1993-03-31

Publications (1)

Publication Number Publication Date
WO1994023067A1 true WO1994023067A1 (fr) 1994-10-13

Family

ID=21913036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003507 WO1994023067A1 (fr) 1993-03-31 1994-03-31 Antigenes associes a des tumeurs reconnus par les lymphocytes et utilisations de ces antigenes

Country Status (2)

Country Link
AU (1) AU6496094A (fr)
WO (1) WO1994023067A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022561A2 (fr) * 1994-02-16 1995-08-24 University Of Virginia Patent Foundation Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications
WO1996021734A2 (fr) * 1995-01-10 1996-07-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
US5844075A (en) * 1994-04-22 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6270778B1 (en) 1994-04-22 2001-08-07 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US7846450B2 (en) 1996-07-11 2010-12-07 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Melanoma associated peptide analogues and vaccines against melanoma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICA ET BIOPHYSICA ACTA, Volume 1080, issued 1991, VLOCK et al., "Purification and Partial Characterization of a Shed 66 kDa Melanoma-Associated Antigen Identified by Autologous Antibody", pages 1-10. *
CELLULAR IMMUNOLOGY, Volume 35, issued 1991, REILLY et al., "Increased Tumor-Specific CTL Activity in Human Tumor-Infiltrating Lymphocytes Stimulated with Autologous Tumor Lines", pages 526-533. *
JOURNAL OF CLINICAL INVESTIGATION, Volume 81, issued June 1988, VLOCK et al., "Isolation and Partial Characterization of Melanoma-Associated Antigens Identified by Autologous Antibody", pages 1746-1751. *
JOURNAL OF IMMUNOLOGY, Volume 149, No. 4, issued 15 August 1992, HAYASHI et al., "Molecular Cloning and Characterization of the Gene Encoding Mouse Melanoma Antigen by cDNA Library Transfection", pages 1223-1229. *
SCIENCE, Volume 255, issued 06 March 1992, HUNT et al., "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry", pages 1261-1263. *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660276B1 (en) 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
WO1995022561A3 (fr) * 1994-02-16 1996-03-07 Univ Virginia Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications
WO1995022561A2 (fr) * 1994-02-16 1995-08-24 University Of Virginia Patent Foundation Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications
US7745212B2 (en) 1994-04-22 2010-06-29 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6965017B2 (en) 1994-04-22 2005-11-15 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US8273724B2 (en) 1994-04-22 2012-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5844075A (en) * 1994-04-22 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US8030280B2 (en) 1994-04-22 2011-10-04 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6270778B1 (en) 1994-04-22 2001-08-07 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6537560B1 (en) 1994-04-22 2003-03-25 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7807805B2 (en) 1994-04-22 2010-10-05 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7803614B2 (en) 1994-04-22 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7763586B2 (en) 1994-04-22 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7749719B2 (en) 1994-04-22 2010-07-06 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7232887B2 (en) 1994-04-22 2007-06-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7612044B2 (en) 1994-04-22 2009-11-03 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
WO1996021734A2 (fr) * 1995-01-10 1996-07-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
WO1996021734A3 (fr) * 1995-01-10 1996-11-28 Us Health Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
WO1997044667A3 (fr) * 1996-05-21 1998-03-19 Pasteur Institut Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules T antigene-specifiques et pour stimuler des cellules T
US7846450B2 (en) 1996-07-11 2010-12-07 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Melanoma associated peptide analogues and vaccines against melanoma
US8075900B2 (en) 1996-07-11 2011-12-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Melanoma associated peptide analogues and vaccines against melanoma
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer

Also Published As

Publication number Publication date
AU6496094A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
US7524930B2 (en) Tumor antigen
KR100380503B1 (ko) 흑색종관련항원성폴리펩티드,그에피토프및흑색종에대한백신
Ferrone et al. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance
Nagata et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Van Els et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance
US7402314B2 (en) In vivo activation of tumor-specific cytotoxic T cells
JP3433322B2 (ja) 腫瘍拒絶抗原先駆体をコード化する核酸分子
US9404925B2 (en) Cancer antigen and use thereof
Petersen et al. Structural investigations of the major allergen Phl p I on the complementary DNA and protein level
JP5198354B2 (ja) メラノーマ関連ペプチド類似体およびメラノーマに対するワクチン
WO1994023067A1 (fr) Antigenes associes a des tumeurs reconnus par les lymphocytes et utilisations de ces antigenes
Schooten et al. T cell epitopes on the 36K and 65K Mycobacterium leprae antigens defined by human T cell clones
CA2326675A1 (fr) Peptides isoles se fixant aux molecules hla-b35
EP1403283A1 (fr) Antigenes tumoraux
CA2079601A1 (fr) Ctaa 28a32, l'antigene reconnu par l'anticorps monoclonal 28a32
Engelhard Direct identification of tumor-associated peptide antigens
JP2002539804A (ja) 生物学的サンプルにおけるスーパー抗原活性を検出する方法
AU752116B2 (en) In vivo activation of tumor-specific cytotoxic T cells
US20030022820A1 (en) In vivo activation of tumor-specific cytotoxic t cells
Sahin et al. Recognition of human tumors: SEREX expression cloning to identify tumour antigens
US20060009393A1 (en) Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
AU767350B2 (en) Melanoma associated peptide analogues and vaccines against melanoma
Klatser et al. T cell epitopes on the 36K and 65K Mycobacterium Zeprae antigens defined by human T cell clones
JP2008521820A (ja) 免疫原性ペプチドを同定および設計するための方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载